Zevra Therapeutics, Inc. ZVRA
Regular-session close
Pre-market · Nov 20, 5:13 AM ET
- YTD
- +1.23%
- 1 year
- +0.22%
5D -2.32 (-19.85%)
- Market cap
- 539.71M
- Revenue (ttm)
- 24.49M
- EPS (ttm)
- 1.22
- Shares out
- 53.38M
- P/E ratio
- 7.43
- Forward P/E
- -22.00
- YTD return
- +1.23%
- 1-year return
- +0.22%
- Volume
- 670.29K
- Avg volume
- 951.49K
- Open
- 9.24
- Previous close
- 9.28
- Day's range
- 9.00 – 9.50
- 52-week range
- 8.01 – 15.04
- Beta
- 1.93
- Price target
- 20.00 (+120.5%)
Key statistics
- 50-day average
- 8.69
- 200-day average
- 6.59
- Enterprise value
- 422.45M
- Price / sales
- 18.70
- Price / book
- 6.54
- Revenue growth
- 27.60%
- Total cash
- 89.38M
- Total debt
- 59.93M
- Return on equity
- -130.67%
- Short % of float
- 8.09%
Fundamental scorecard
17 of 25 checks passed on ZVRA’s reported financials
17of 25 checks passed
- Value 4 of 5
- Growth 4 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.44 | -0.69 | -0.25 | -56.82% |
| Aug 13, 2024 | Jun 1, 2024 | -0.47 | -0.48 | -0.01 | -2.13% |
| May 8, 2024 | Mar 1, 2024 | -0.49 | -0.40 | +0.09 | +18.37% |
| Mar 28, 2024 | Dec 1, 2023 | -0.20 | -0.40 | -0.20 | -100.00% |
| Nov 7, 2023 | Sep 1, 2023 | -0.29 | -0.40 | -0.11 | -37.93% |
| Aug 14, 2023 | Jun 1, 2023 | -0.39 | -0.15 | +0.24 | +61.54% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Oct 11, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Oct 7, 2024 | Guggenheim | init | — | Buy |
| Oct 1, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Sep 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zevra.com
News
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $18
BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $21
Zevra Therapeutics Says CHMP Adopts Negative Opinion On MAA For Arimoclomol For Treatment Of Niemann-Pick Disease Type C; European Commission Expected To Issue Final Decision On MAA Within 67 Days
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Zevra Therapeutics Q3 2026 Earnings Call Transcript Zevra Therapeutics Q3 EPS $0.26 Beats $0.16 Estimate, Sales $37.756M Beat $37.079M Estimate
Your note
Sign in to keep a note on ZVRA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Woodline Partners LP | 93.83% | 4,048,653 | 34.74M | Sep 29, 2024 |
| Blackrock Inc. | 72.35% | 3,121,759 | 26.78M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 67.77% | 2,924,021 | 25.09M | Sep 29, 2024 |
| Vanguard Group Inc | 63.88% | 2,756,061 | 23.65M | Sep 29, 2024 |
| FMR, LLC | 53.61% | 2,313,202 | 19.85M | Sep 29, 2024 |
| Altium Capital Management, LP | 39.40% | 1,700,000 | 14.59M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 38.65% | 1,667,443 | 14.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 25.11% | 1,083,492 | 9.30M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 17.13% | 739,174 | 6.34M | Sep 29, 2024 |
| Fidelity Advisor Equity Growth Fund | 15.29% | 659,820 | 5.66M | Oct 30, 2024 |
| Variable Insurance Products Fund-Growth Portfolio | 14.88% | 642,100 | 5.51M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 9.96% | 429,600 | 3.69M | Aug 30, 2024 |
